Biology Immunology
News
22 May 2026
Position of a RELA mutation can shape symptoms, severity and treatment response
21 May 2026
Researchers from The University of Osaka found that only a small subset of tumor-killing T cells undergoes extensive expansion during immunotherapy for multiple myeloma. By tracking individual cells, the team showed that the T-cell clones that later became dominant had already begun expanding shortly after the treatment started. The findings also suggest that highly proliferative immune cells show lower levels of exhaustion-related markers, offering new insights into why some patients respond better to immunotherapy.
23 Apr 2026
Researchers from The University of Osaka have discovered a new class of antibodies, called iTabs, that naturally suppress specific immune responses by blocking immune cell activation. These antibodies can reduce autoimmune disease severity in mice, suggesting a new way to treat conditions like multiple sclerosis without weakening the immune system overall.
14 Apr 2026
Matcha surprise, Smart sea urchin spines, Breaking biomass bonds, Hybrid air-conditioning, Alga in gloom & A touch of tech. Read all in the latest Editor's Choice. Plus Early Bird submissions for Asia Research News 2027
14 Apr 2026
Researchers from The University of Osaka have shown that the MIC11 gene of Toxoplasma gondii is essential for the parasite to egress, or exit, the host cell, a key part of the lifecycle. Deletion of MIC11 caused parasites to be unable to permeabilize host cell membranes and prevented egress. This study identifies potential new therapeutic targets for human diseases caused by parasites, such as toxoplasmosis and malaria, which represent a major global health problem.
17 Mar 2026
We identified Mrep macrophages that repair muscle but trigger heterotopic ossification in FOP, advancing muscle and FOP therapy development.
11 Mar 2026
The famed Japanese green tea powder may suppress nerve activity associated with sneezing in hay fever, according to a study in mice.
05 Mar 2026
Testing air and surfaces can detect dangerous viruses earlier and more comprehensively than testing birds alone
22 Dec 2025
A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of inducing antigen-specific regulatory T cells (Tregs), the immune cells that play a central role in suppressing excessive immune responses. The findings, now published in Drug Delivery, may pave the way for next-generation therapies for autoimmune and allergic diseases, where unwanted immune activation must be precisely controlled.
14 Nov 2025
Untangling cosmic knots, Samurai jellyfish, Controlling rogue antibodies, Search for anti-ulcer vaccine & Metal-recovering yeast. Plus next SciCom coffee talk on experiences in science journalism in the AI era and WHO guide to reporting on non communicable diseases. Read all in the latest Editor's Choice.
14 Oct 2025
SOSE researchers are looking at a possible vaccine for H. pylori, a widely common bacterium that causes stomach ulcers and raises the risk for stomach cancer.
08 Oct 2025
Researchers at The University of Osaka have discovered precursor T follicular regulatory cells (preTfr), comprising 30-50% of circulating Tfr in human blood. preTfr are significantly reduced in severe COVID-19 and sepsis, correlating with increased anti-interferon-gamma autoantibodies and activated atypical B cells. Unlike stable conventional naïve regulatory T cells, preTfr are specifically depleted during severe disease. When stimulated, preTfr up-regulate suppressive molecules including IL-1RA and show enhanced wound healing capacity. Conversely, mRNA vaccination increases preTfr frequency, suggesting controlled immune participation. The findings identify preTfr as a therapeutic target for preventing autoantibody production during severe infections.
11 Sep 2025
An international research group led by The University of Osaka has developed scODIN, a novel computational tool to classify cell types from single-cell RNA sequencing (scRNA-seq) data. Existing methods struggle to balance speed and accuracy, often misclassifying rare or transitional cells. scODIN overcomes this limitation by combining a hierarchical classification system (Tier system) with k-nearest neighbor inference. This approach allows for the rapid and accurate classification of large datasets, processing 650,000 cells in just six minutes. The tool's improved accuracy stems from its ability to identify cells at varying levels of detail, recognize intermediate phenotypes through double labeling, and recover cells affected by dropout events. scODIN promises to accelerate biomedical discoveries by enabling more precise and efficient analysis of complex biological processes and disease mechanisms.
03 Sep 2025
A customizable protein has been developed to help the body remove harmful cells, such as those involved in cancer or autoimmune diseases, offering a potential new direction for treatments.
02 Sep 2025
Researchers from The University of Osaka found that macrophages use microautophagy, mediated by Rab32-positive lysosome-related organelles, to directly engulf damaged mitochondria and other organelles. This was discovered to be independent of macroautophagy. Key factors in this process include Rab32 GTPase, PI(3,5)P2, ubiquitination, and p62/SQSTM1. By clearing mitochondria, microautophagy promotes metabolic reprogramming toward glycolysis, supporting M1 macrophage polarization. Loss of Rab32/38 disrupts this process, highlighting microautophagy’s role in regulating macrophage function.
20 Aug 2025
Professor Ogawa, Mr. Echigo (PhD student), and their colleagues in Kanazawa University report in Eur J Nucl Med Mol Imaging that combination of an At-211-labeled agent with immune checkpoint blockade significantly enhances its therapeutic effect. This strategy represents a promising advancement in the development of next-generation cancer therapies that combine targeted alpha therapy and immunotherapy.
18 Jul 2025
A team from The University of Osaka found that the intestinal flora works together with the OTUD3 and STING genes to aggravate ulcerative colitis, a disease with no cure that causes major intestinal pain and bloody diarrhea. When the OTUD3 gene is mutated, microbes in the intestinal flora trigger STING signalingOTUD, leading to inflammation in the colon. The intestinal flora and STING signaling may be important new targets for ulcerative colitis treatment.
17 Jun 2025
Researchers from The University of Osaka found that EGR1-expressing CD14+ monocytes and CD8+ T cells with a type II interferon signature are associated with scleroderma renal crisis and interstitial lung disease, respectively, in patients with systemic sclerosis. Understanding the specific immune cell abnormalities underlying different clinical manifestations of the disease could help predict and prevent serious complications.
24 Apr 2025
Researchers from The University of Osaka discover that specific white blood cells and the amount of an inflammation protein in the blood can predict relapse of an autoimmune blood vessel disease.
14 Apr 2025
Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally occurring particles called extracellular vesicles (EVs), they have created a way to boost the body’s immune system to fight tumors more effectively. This breakthrough could lead to more targeted cancer therapies with fewer side effects.
24 Jan 2025
At Duke-NUS Medical School scientists are pioneering breakthroughs in precision medicine and regenerative therapies, targeting everything from muscle loss to dramatically extending our years of health.
15 Nov 2024
• This breakthrough test requires only a small blood sample to track modified T cells in patients over time, ensuring therapies remain effective.
• This plug-and-play approach is set to accelerate the development of more T-cell-based therapies and vaccines.
13 Sep 2024
Researchers from Osaka University found that T cells recognize neoself-antigens––abnormal, unfolded host proteins presented by major histocompatibility complex II (MHC-II) lacking the invariant chain––as non-self antigens, leading to the development of autoimmunity. Reactivation of Epstein–Barr virus, a known risk factor for lupus onset and exacerbation, increases the presentation of neoself-antigens by MHC-II, which could help explain the link between viral infection and autoimmune disease.
22 Aug 2024
A newly developed compound that reduces harmful inflammation in rats caused by overactive neutrophils shows great potential as a safer treatment for various inflammatory diseases in humans.
21 Aug 2024
Researchers from Osaka University find that the transcription factor Ikaros binds to Foxp3 to inhibit the expression of target genes, including Ifng, in regulatory T cells
18 Jul 2024
Combination of venetoclax and azacitidine helps patients with AML who relapse after hematopoietic cell transplant
12 Mar 2024
A new study highlights a potential therapeutic target for immune-related disorders, such as multiple sclerosis and asthma.
14 Nov 2023
Cancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.
13 Nov 2023
New study finds prior dengue antibodies substantially raise risk of microcephaly, foetal defects with Zika infection.
02 Oct 2023
The authors discovered a shorter isoform of Rubicon called RUBCN100, which enhances autophagy in B cells.
Events
Sorry, nothing coming up for this discipline
Researchers
Dr Sarkar is a senior research fellow at the Murdoch Children's Research Institute in Melbourne, Australia. She is
actively engaged in collaborating with academic and industry stakeholders and leads multiple projects for the development of novel therapeutics/vaccines to tackle antimicrobial resistance.
Dr. Cheng-Siang Tan is an Associate Professor at the Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak (UNIMAS). He is an expert in infectious and emerging diseases and biosafety and biorisk management.
Dr. Ashfaq Ahmad Shah 'اشفاک,' born on 6 June 1992, from south Kashmir, Dodarkoot ددیرکوٹ Kulgam, Jammu and Kashmir, India, is the microbiologist whose broad area of specialization incorporates infection immunity. He served as a researcher at the Graphic Era (Deemed to be University), Dehradun, UK, India, from 2020 to 2025. Currently he is working as Postdoctoral researcher and Junior Scientist in the KIET School of Pharmacy at KIET University. As a microbiology scientist, Dr. Shah has pursued novel dimensions of infection immunity pertaining to the correlation and impact of elicitation-triggered phytoalexins and phytoanticipins on the benign immune system of human beings. This parameter of immunology is termed phytoalexin-immunomodulation scrutiny in the contemporary era. Dr. Shah's research encompasses a range of areas, including the indagation on anti-inflammatory and antimicrobial compounds, evaluation of antibiotic resistance, study of immunomodulatory activities, disease model studies, protease isolation against specific protein antigens, study of novel compounds via the hyphenated techniques of GCMS, HPLC, FTIR-MS, etc., and the discipline of kalology, including tyrosinase inhibition, PPO inhibition, skin whitening agents, kerato-peeling, etc. Dr. Ashfaq is a scientist, doctoral researcher, reviewer, and editorial member of several journals and books of national and international repute. He has contributed extensively to scientific literature by publishing his research in journals of national and international repute. So far he has published more than forty infection/immunology/pharmacology scientific papers in Scopus and SCI-indexed journals, including two international books. In recognition of his contributions, Dr. Shah received the Young Scientist Award in August 2023 for his groundbreaking academic performance in the field of infection immunity. Dr. Shah has also been an active editor of Wikipedia pages in the field of medical science since 2015, with more than 1000 edits in medical topics available to medical literature worldwide.
Dr. Tay has researched antibodies and diseases like malaria and SARS-CoV-2 at A*STAR. His focus is on discovering methods for developing antibodies that can be used in therapies against multidrug-resistant pathogens.
Dr. Singhal serves as senior principal investigator at the Bacterial Immunopathology Lab at A*STAR ID Labs in Singapore. His work at A*STAR ID Labs revolves around three main pathogens: Mycobacterium tuberculosis, Gram-negative bacteria and Dengue virus.
Dr. Bifani is a principal investigator at A*STAR ID Labs at their Antimicrobial Resistance Lab. He has extensively researched antimicrobial resistance in tuberculosis and malaria. He is also an associate professor and research director at the Yong Yoo Lin School of Medicine, National University of Singapore.
Professor and Head of Microbiology and Immunology Department,
Faculty of Medicine, Lincoln University College (LUC) Malaysia.
Giants in history
Husband and wife team, Kimishige (3 December 1925 – 6 July 2018) and Teruko Ishizaka (28 September 1926 – 4 June 2019) discovered the antibody class Immunoglobulin E (IgE) that triggers allergic reactions. They also discovered that IgE antibodies attach to white blood cells, known as mast cells, releasing histamine, which causes allergic reactions.
Husband and wife team, Kimishige (3 December 1925 – 6 July 2018) and Teruko Ishizaka (28 September 1926 – 4 June 2019) discovered the antibody class Immunoglobulin E (IgE) that triggers allergic reactions. They also discovered that IgE antibodies attach to white blood cells, known as mast cells, releasing histamine, which causes allergic reactions.